Joshua Zhang

3.2k total citations · 1 hit paper
56 papers, 894 citations indexed

About

Joshua Zhang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Joshua Zhang has authored 56 papers receiving a total of 894 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 29 papers in Pulmonary and Respiratory Medicine and 27 papers in Surgery. Recurrent topics in Joshua Zhang's work include Renal cell carcinoma treatment (23 papers), Cancer Immunotherapy and Biomarkers (21 papers) and Spine and Intervertebral Disc Pathology (15 papers). Joshua Zhang is often cited by papers focused on Renal cell carcinoma treatment (23 papers), Cancer Immunotherapy and Biomarkers (21 papers) and Spine and Intervertebral Disc Pathology (15 papers). Joshua Zhang collaborates with scholars based in United States, France and Germany. Joshua Zhang's co-authors include Robert J. Motzer, Toni K. Choueiri, Andrea B. Apolo, Burçin Şimşek, Cristina Suárez, Christian Scheffold, Thomas Powles, Amishi Y. Shah, Bernard Escudier and Mauricio Burotto and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Lancet Oncology.

In The Last Decade

Joshua Zhang

44 papers receiving 884 citations

Hit Papers

Nivolumab plus cabozantin... 2022 2026 2023 2024 2022 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial
    2022 177 citations Robert J. Motzer, Thomas Powles et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joshua Zhang United States 15 668 488 375 279 179 56 894
Alessia Mennitto Italy 19 479 0.7× 549 1.1× 271 0.7× 225 0.8× 212 1.2× 59 1.0k
Tom Waddell United Kingdom 7 567 0.8× 427 0.9× 269 0.7× 207 0.7× 131 0.7× 18 715
Sandhya Srinivas United States 9 396 0.6× 479 1.0× 250 0.7× 199 0.7× 78 0.4× 18 748
Ronan Flippot France 18 826 1.2× 630 1.3× 567 1.5× 412 1.5× 196 1.1× 80 1.3k
Vesna Šneller United States 7 582 0.9× 360 0.7× 584 1.6× 361 1.3× 102 0.6× 12 995
Amin H. Nassar United States 17 396 0.6× 454 0.9× 318 0.8× 216 0.8× 250 1.4× 74 886
Charles Schloss United States 16 742 1.1× 653 1.3× 341 0.9× 235 0.8× 129 0.7× 67 981
Symantha Melemed United States 12 1.2k 1.7× 990 2.0× 236 0.6× 190 0.7× 123 0.7× 16 1.4k
Rustem Gafanov Russia 17 1.2k 1.8× 846 1.7× 570 1.5× 438 1.6× 300 1.7× 49 1.4k
David F. McDermott United States 8 572 0.9× 441 0.9× 510 1.4× 294 1.1× 109 0.6× 12 915

Countries citing papers authored by Joshua Zhang

Since Specialization
Citations

This map shows the geographic impact of Joshua Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joshua Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joshua Zhang more than expected).

Fields of papers citing papers by Joshua Zhang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joshua Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joshua Zhang. The network helps show where Joshua Zhang may publish in the future.

Co-authorship network of co-authors of Joshua Zhang

This figure shows the co-authorship network connecting the top 25 collaborators of Joshua Zhang. A scholar is included among the top collaborators of Joshua Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joshua Zhang. Joshua Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Zhang, Joshua, Tejas Subramanian, Annette Ehrlich, et al.. (2025). Uniportal Endoscopic Microdiscectomy Is an Effective Treatment Option for Far-Lateral Lumbar Disk Herniations. HSS Journal® The Musculoskeletal Journal of Hospital for Special Surgery. 22(2). 138–144.
3.
4.
5.
Vaishnav, Avani S., Kasra Araghi, Nishtha Singh, et al.. (2024). Discrepancy between global- and disease-specific outcome measures following lumbar spine surgery. Journal of Neurosurgery Spine. 41(5). 648–657.
6.
Rohde, Matthew, Junho Song, Austen Katz, et al.. (2024). Association between modifiable and nonmodifiable risk factors with paralumbar muscle health in patients with lower back pain. North American Spine Society Journal (NASSJ). 20. 100570–100570.
7.
8.
Zhang, Joshua, Amy Lu, Patawut Bovonratwet, et al.. (2024). Predictors for Failure to Respond to Erector Spinae Plane Block Following Minimally Invasive Transforaminal Lumbar Interbody Fusion. Spine. 49(23). 1669–1675.
9.
Asada, Tomoyuki, Tejas Subramanian, Takashi Hirase, et al.. (2024). Level-specific comparison of 3D navigated and robotic arm-guided screw placement: an accuracy assessment of 1210 pedicle screws in lumbar surgery. The Spine Journal. 24(10). 1872–1880. 8 indexed citations
10.
11.
Galsky, Matthew D., Dean F. Bajorin, J. Alfred Witjes, et al.. (2023). Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score. European Urology. 83(5). 432–440. 14 indexed citations
12.
Galsky, Matt D., Jürgen E. Gschwend, Michael Schenker, et al.. (2023). Extended follow-up results from the CheckMate 274 trial.. Journal of Clinical Oncology. 41(6_suppl). LBA443–LBA443. 13 indexed citations
13.
14.
Suárez, Cristina, Toni K. Choueiri, Mauricio Burotto, et al.. (2022). Association between depth of response (DepOR) and clinical outcomes: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 9ER.. Journal of Clinical Oncology. 40(16_suppl). 4501–4501. 9 indexed citations
15.
Shah, Amishi Y., Robert J. Motzer, Andrea B. Apolo, et al.. (2021). Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N+C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC).. Journal of Clinical Oncology. 39(15_suppl). 4561–4561. 7 indexed citations
16.
Huan, Chongmin, et al.. (2019). Loss of Reg proteins' protection of islet β cells in chronic pancreatitis: A potential mechanism for the pathogenesis of type 3c diabetes. Current Opinion in Endocrine and Metabolic Research. 5. 21–28. 2 indexed citations
17.
Vogelzang, Nicholas J., Joshua J. McFarlane, Mark D. Kochenderfer, et al.. (2019). Efficacy and safety of nivolumab in patients with non-clear cell renal cell carcinoma (RCC): Results from the phase IIIb/IV CheckMate 374 study.. Journal of Clinical Oncology. 37(7_suppl). 562–562. 13 indexed citations
18.
19.
Choueiri, Toni K., Andrea B. Apolo, Thomas Powles, et al.. (2018). A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER).. Journal of Clinical Oncology. 36(15_suppl). TPS4598–TPS4598. 27 indexed citations
20.
Eskens, Ferry A.L.M., Corina N.A.M. Oldenhuis, Walter J. Loos, et al.. (2012). Final results of a phase Ib study of tivozanib and FOLFOX6 in patients (pts) with advanced gastrointestinal (GI) tumors.. Journal of Clinical Oncology. 30(15_suppl). 4132–4132. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alessia Mennitto Breakdown of academic impact, for papers by Tom Waddell Breakdown of academic impact, for papers by Sandhya Srinivas Breakdown of academic impact, for papers by Ronan Flippot Breakdown of academic impact, for papers by Vesna Šneller Breakdown of academic impact, for papers by Amin H. Nassar Breakdown of academic impact, for papers by Charles Schloss Breakdown of academic impact, for papers by Symantha Melemed Breakdown of academic impact, for papers by Rustem Gafanov Breakdown of academic impact, for papers by David F. McDermott
Rankless by CCL
2026